

Alcon medical device(s) comply with the current legislation for the medical devices. Please refer to relevant product's instructions for use for complete list of indications, contraindications, warnings and serious incidents. Please find at: <https://ifu.alcon.com/>

Some product(s) may not be approved in your country. Please check the availability with your local sales representative.

[^]*Trademarks are the property of their respective owners.*

^{*}*Based on worldwide unit sales of AcrySof IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024.*

[†]*Based on worldwide IOL unit sales, Q1-Q3, 2023.*

[‡]*Compared to Clareon PanOptix*

[§]*Compared to Clareon PanOptix. PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light).*

[¶]*Visual disturbance assessment through a visual simulation in phakic patients. Assessor masked to IOLs.*

^Δ*Subjects were presented a night scene set at 4m and viewing LEDs and asked to say which IOL they prefer for 1) Starburst and 2) Halo*

^Ω*Based on a Monocular defocus curve in a virtual simulation with phakic patients & subjective preference of IOL at intermediate defocus when viewing 0.2 logMAR. Assessor masked to IOLs.*

^{**}*Question: Which IOL do you prefer viewing the 0.2 logMAR line at intermediate distance?*

^{††}*Based on a Monocular defocus curve in a virtual simulation with phakic patients. Assessor masked to IOLs.*

^{‡‡}*Based on mean value of binocular defocus curve at near, intermediate, and distance at 6 months (n=127*

^{§§}*Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopathy Study chart letters in the line were identified correctly.*

^{¶¶}*Results from a prospective, randomized, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity Extended Vision IOL and 113 with the AcrySof IQ IOL with 6 months' follow-up.*

References

1. Alcon data on file, 2024. REF-26299.
2. MarketScope LLC. 2024 Premium Cataract Surgery Market Report. Published October 2024. St. Louis, MO: MarketScope LLC; 2024.
3. Alcon data on file, 2024. REF-23554.
4. MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023.
5. Alcon data on file, 2025. REF-28549.
6. Alcon data on file, 2025. REF-28331.
7. Alcon data on file, 2025. REF-28335.
8. Clareon® Vivity® Extended Vision Hydrophobic IOL (CNWET0) Directions for Use
9. Alcon Data on File, 2024. REF-25409.
10. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. *Clinical Ophthalmology*. 2023;Volume 17:155-163. doi:10.2147/oph.s377234.
11. Alcon data on file, 2024. REF-23958.
12. Alcon data on file, 2023. REF-26241.
13. Das KK, Werner L, Collins S, Hong X. In vitro and schematic model eye assessment of glare or positive dysphotopsia-type photic phenomena: Comparison of a new material IOL to other monofocal IOLs. *J Cataract Refract Surg*. 2019;45(2):219-227.
14. Lehmann R, Maxwell A, Lubeck DM, Fong R, Walters TR, Fakadej A. Effectiveness and safety of the Clareon Monofocal intraocular lens: Outcomes from a 12-month single arm clinical study in a large sample. *Clin Ophthalmol*. 2021;15:1647-1657.
15. Alcon data on file, 2025. REF-28698.
16. Alcon data on file, 2025. REF-28699.
17. Alcon data on file, 2025. REF-25218.
18. Alcon data on file, 2015. REF-08546.
19. Alcon data on file, 2025; REF-27901.
20. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021.
21. Zavodni ZJ, Solomon KD, Sreenivasan V, Patel TR, Hull JM. Visual Outcomes Through a Next Generation Trifocal Lens. Presented at ASCRS, April 10-13, 2026, Washington D.C.
22. Alcon Data on File, 2022. REF-15172.
23. McCabe C, Berdahl J, Reiser H, et al. Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a non-diffractive design. *J Cataract Refract Surg*. 2022;48(11):1297-1304. doi:10.1097/j.jcrs.0000000000000978.
24. Alcon Data on File, 2024. REF-25409.
25. Alcon data on file, 2026. REF-28847
26. Alcon data on file, 2025; REF-28362.